Compare Crispr Therapeutics AG (CRSP) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kroger Co — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while Kroger Co trades at $61.28 (market cap $34.99B). The key difference: Kroger Co is far larger — about 6.9× Crispr Therapeutics AG's market cap, and Kroger Co pays a 2.63% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Kroger Co for 108 Days on average.
| CRSP | KR | |
|---|---|---|
Market Cap | $5.06B | $34.99B |
Volume | 1,678,371 | 8,938,607 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $75.60 |
52-Week Low | $44.34 | $55.53 |
Typical Hold Time | 77 Days | 108 Days |
Enterprise Value | $3.48B | $56.41B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Kroger (KR) trades at $61.41, up 5.14% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with $147.12B in revenue, though net margins remain thin at 0.73%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. The company maintains positive cash flow generation and continues dividend payments while facing competitive pressures in the grocery sector.
Kroger presents a balanced investment case with attractive valuation metrics (P/S 0.25) and analyst consensus pointing to 15% upside to $70.62 target. However, risks include integration challenges from acquisitions, margin pressure from price competition, and softer 2026 sales guidance. The stock offers value characteristics with dividend yield support amid ongoing digital transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
